MK-0873   Click here for help

GtoPdb Ligand ID: 9853

Synonyms: compound 20 [PMID: 18835163] | MK0873
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: MK-0873 is an optimized investigational PDE4 inhibitor with favourable in vitro and in vivo profiles that support clinical development [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 90.41
Molecular weight 422.14
XLogP 5.74
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES [O-][n+]1cccc(c1)C#Cc1cccc(c1)n1cc(C(=O)NC2CC2)c(=O)c2c1nccc2
Isomeric SMILES [O-][n+]1cccc(c1)C#Cc1cccc(c1)n1cc(C(=O)NC2CC2)c(=O)c2c1nccc2
InChI InChI=1S/C25H18N4O3/c30-23-21-7-2-12-26-24(21)29(16-22(23)25(31)27-19-10-11-19)20-6-1-4-17(14-20)8-9-18-5-3-13-28(32)15-18/h1-7,12-16,19H,10-11H2,(H,27,31)
Immunopharmacology Comments
MK-0873 is a PDE4 inhibitor that was a clinical candidate for inflammatory diseases. It inhibits LPS-induced production of TNF-α in human whole blood assays. No clinical trial results appear to have been published in peer reviewed literature.
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
Completed Phase 2 trial for plaque psoriasis- see NCT01140061
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Completed Phase 2 trial for RA- see NCT00132769